Bratislava Medical Journal Vol.120, No.8, p.601

Bratislava Medical Journal Vol.120, No.8, p.601–603, 2019

Published Monthly, in English
Founded: 1919
ISSN 0006-9248
(E)ISSN 1336-0345

Impact factor 1.5

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Bratislava Medical Journal Vol.120, No.8, p.601–603, 2019
Title: The effect of GnRH agonists on angiogenesis and its implications for the myocardium in patients with cardiac risk
Author: Z. Valaskova, I. Hulin, O. El Hassoun, S. Polak, B. Mladosievicova

Abstract: Gonadotropin-releasing hormone agonists were described as anti-angiogenic factors in tumors. Simultaneously they were associated with increased cardiovascular risk in patients treated for prostate cancer, especially in those with preexisting cardiac disease. Studies aiming to elucidate the mechanisms by which androgen deprivation therapy causes cardiovascular effects are rare. We believe that gonadotropin-releasing hormone agonists can impair myocardial angiogenesis. That, in patients with myocardial disease can deepen hypoxia, significantly worsen the condition of the myocardium, and therefore increase the risk of cardiac failure. Careful assessment of the myocardial status and consequent timing and typing of therapy can minimalize the adverse effects. Ideally through close cooperation between cardiologists and oncologists (Fig. 1, Ref. 25).

Keywords: angiogenesis, cardiovascular risk, follicle stimulating hormone, GnRH agonist, testosterone
	Published online: 29-Jul-2019
Year: 2019, Volume: 120, Issue: 8	Page From: 601, Page To: 603
doi:10.4149/BLL_2019_098
	download file

Aepress.sk